Samar Issa

2.4k citations

50 papers · 1.6k indexed · 1 hit paper · h-index 15

Impact in

Genetics top 1%
- Chronic Lymphocytic Leukemia Research
- Glioma Diagnosis and Treatment
Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment

Papers in ⓘ

Genetics 29
- Chronic Lymphocytic Leukemia Research 17
- Glioma Diagnosis and Treatment 12
Neurology 28
- CNS Lymphoma Diagnosis and Treatment 28

Co-authors: David Simpson (14 shared papers)Peter Wood (12 shared papers)Kathryn S. Kolibaba (10 shared papers)Ian W. Flinn (10 shared papers)David MacDonald (10 shared papers)John M. Burke (10 shared papers)Tim E. Hawkins (9 shared papers)Brad S. Kahl (8 shared papers)
Journals: Blood (16 papers)Journal of Clinical Oncology (7 papers)Neuro-Oncology (6 papers)Hematological Oncology (3 papers)Annals of Oncology (2 papers)
Partner nations: New Zealand Australia United States

In The Last Decade

Samar Issa

49 papers receiving 1.5k citations

Hit Papers

align trajectories log scale

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study 2014 · 419 citations

Peers

Countries citing papers authored by Samar Issa

Since Specialization

Citations

This map shows the geographic impact of Samar Issa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samar Issa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samar Issa more than expected).

Fields of papers citing papers by Samar Issa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samar Issa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samar Issa. The network helps show where Samar Issa may publish in the future.

Co-authors

The 25 scholars most cited alongside Samar Issa, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Samar Issa Line = papers co-authored together Samar Issa links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 50 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study Blood ·Ian W. Flinn, Richard van der Jagt, Brad S. Kahl, Peter Wood, Tim E. Hawkins, David MacDonald, Mark Hertzberg, Yiu‐Lam Kwan, David Simpson, Michael Craig, Kathryn S. Kolibaba, Samar Issa, Regina Clementi, Doreen M. Hallman, Mihaela Munteanu, Ling Chen, John M. Burke Hit paper breakdown →	2014	419
2	Phase I Study of Intraventricular Administration of Rituximab in Patients With Recurrent CNS and Intraocular Lymphoma Journal of Clinical Oncology ·James L. Rubenstein, Jane Fridlyand, Lauren E. Abrey, Arthur Shen, Jon Karch, Endi Wang, Samar Issa, Lloyd E. Damon, Michael D. Prados, Michael McDermott, Joan M. O’Brien, Chris Haqq, Marc Shuman	2007	243
3	First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study Journal of Clinical Oncology ·Ian W. Flinn, Richard van der Jagt, Brad S. Kahl, Peter Wood, Tim E. Hawkins, David MacDonald, David Simpson, Kathryn S. Kolibaba, Samar Issa, Julie Chang, Judith Trotman, Doreen M. Hallman, Ling Chen, John M. Burke	2019	166
4	Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study The Lancet Oncology ·Jacoline E. C. Bromberg, Samar Issa, Katerina Bakunina, Monique C. Minnema, Tatjana Seute, Marc Durian, Gavin Cull, Harry C. Schouten, Wendy B.C. Stevens, Josée M. Zijlstra, Joke W. Baars, Marcel Nijland, Kylie D. Mason, Aart Beeker, Martin J. van den Bent, Max Beijert, Michael Gonzales, Daphne de Jong, Jeanette K. Doorduijn	2019	162
5	Immunochemotherapy with Intensive Consolidation for Primary CNS Lymphoma: A Pilot Study and Prognostic Assessment by Diffusion-Weighted MRI Clinical Cancer Research ·Matthew J. Wieduwilt, Francisco Valles, Samar Issa, Caroline Behler, James Q. Hwang, Michael McDermott, Patrick Treseler, Joan M. O’Brien, Marc A. Shuman, Soonmee Cha, Lloyd E. Damon, James L. Rubenstein	2012	99
6	Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study Blood ·Jorge J. Castillo, Gilad Itchaki, Jonas Paludo, Marzia Varettoni, Christian Buske, Toby A. Eyre, Julio C. Chávez, Kenneth H. Shain, Samar Issa, M. Lia Palomba, Oren Pasvolsky, David Simpson, Dipti Talaulikar, Constantine S. Tam, Alessandra Tedeschi, Stephen M. Ansell, Lakshmi Nayak, Steven P. Treon	2018	63
7	Rituximab in primary central nervous system lymphoma—A systematic review and meta‐analysis Hematological Oncology ·Andreas M. Schmitt, Amanda K. Herbrand, Christopher P. Fox, Katerina Bakunina, Jacoline E. C. Bromberg, Kate Cwynarski, Jeanette K. Doorduijn, Andrés J.M. Ferreri, Gerald Illerhaus, Samar Issa, Elisabeth Schorb, Emanuele Zucca, Lars G. Hemkens, Stefan Schandelmaier, Benjamin Kasenda	2019	51
8	Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation - an International Primary Central Nervous System Lymphoma Study Group project Haematologica ·Jacoline E. C. Bromberg, Jeanette K. Doorduijn, Gerald Illerhaus, Kristoph Jahnke, Agnieszka Korfel, L. Fischer, Kristina Fritsch, Outi Kuittinen, Samar Issa, C. van Montfort, Martin J. van den Bent	2012	43
9	Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma Annals of Oncology ·Maurilio Ponzoni, Samar Issa, Tracy T. Batchelor, James L. Rubenstein	2013	37
10	Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience British Journal of Haematology ·Katharine L. Lewis, Collin K. Chin, Kate Manos, John Casey, Nada Hamad, Julie Crawford, Shir‐Jing Ho, Samar Issa, Andrew Grigg, Peter Wood, Maher K. Gandhi, Bryan Do, Loretta J. Nastoupil, Eliza A. Hawkes, Chan Y. Cheah	2020	31
11	An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study Blood ·Ian W. Flinn, Richard H. van der Jagt, Brad S. Kahl, Peter Wood, Tim E. Hawkins, David MacDonald, Mark Hertzberg, Yiu‐Lam Kwan, David Simpson, Michael Craig, Kathryn S. Kolibaba, Samar Issa, Mihaela Munteanu, Regina Clementi, Ling Chen, John M. Burke	2012	26
12	Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial Blood ·David T Yeung, Michael Osborn, Deborah L. White, Susan Branford, Michael Kornhauser, Cassandra Slader, Samar Issa, Devendra Hiwase, Mark Hertzberg, Anthony P. Schwarer, Robin Filshie, Christopher Arthur, Yiu Lam Kwan, Cecily Forsyth, David M. Ross, Anthony K. Mills, Andrew Grigg, Timothy P. Hughes	2011	23
13	Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost–benefit and quality of life analysis Supportive Care in Cancer ·Sophie Lee, Angela Knox, Irene Zeng, Christin Coomarasamy, Hilary Blacklock, Samar Issa	2012	18
14	Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Clinical Lymphoma Myeloma & Leukemia ·John M. Burke, Richard H. C. Van Der Jagt, Brad S. Kahl, Peter Wood, Tim E. Hawkins, David MacDonald, Mark Hertzberg, David Simpson, Michael Craig, Kathryn S. Kolibaba, Samar Issa, Mihaela Munteanu, Timothy W. Victor, Ian W. Flinn	2016	14
15	MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma Journal of Neuro-Oncology ·Matthijs van der Meulen, Linda Dirven, Katerina Bakunina, Martin J. van den Bent, Samar Issa, Jeanette K. Doorduijn, Jacoline E. C. Bromberg	2021	14
16	Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial Blood ·David T Yeung, Michael Osborn, Deborah L. White, Susan Branford, Michael Kornhauser, Cassandra Slader, Samar Issa, Devendra Hiwase, Mark Hertzberg, Anthony P. Schwarer, Robin Filshie, Christopher Arthur, Yiu Lam Kwan, Cecily Forsyth, David M. Ross, Anthony K. Mills, Andrew Grigg, Timothy P. Hughes, (unknown)	2012	14
17	First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study. Journal of Clinical Oncology ·Ian W. Flinn, Richard van der Jagt, Julie Chang, Peter Wood, Tim E. Hawkins, David MacDonald, Judith Trotman, David Simpson, Kathryn S. Kolibaba, Samar Issa, Doreen M. Hallman, Ling Chen, John M. Burke	2017	13
18	Extent of radiological response does not reflect survival in primary central nervous system lymphoma Neuro-Oncology Advances ·Matthijs van der Meulen, Alida A. Postma, Marion Smits, Katerina Bakunina, Monique C. Minnema, Tatjana Seute, Gavin Cull, Roelien H. Enting, Marjolein van der Poel, Wendy B.C. Stevens, Dieta Brandsma, Aart Beeker, Jeanette K. Doorduijn, Samar Issa, Martin J. van den Bent, Jacoline E. C. Bromberg	2021	12
19	Primary central nervous system lymphoma: epidemiology and clinical presentation Kun-Wei Song, Samar Issa, Tracy T. Batchelor	2021	11
20	Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial Blood ·Brad S. Kahl, John M. Burke, Richard van der Jagt, Julie Chang, Peter Wood, Tim E. Hawkins, David MacDonald, Judith Trotman, David Simpson, Kathryn S. Kolibaba, Samar Issa, Doreen M. Hallman, Ling Chen, Ian W. Flinn	2017	10

About Samar Issa

Samar Issa is a scholar working on Genetics, Neurology, Pathology and Forensic Medicine, Hematology and Oncology, having authored 50 papers that have together received 1.6k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (31 papers), CNS Lymphoma Diagnosis and Treatment (28 papers), Chronic Lymphocytic Leukemia Research (17 papers), Glioma Diagnosis and Treatment (12 papers), Chronic Myeloid Leukemia Treatments (7 papers), Lung Cancer Treatments and Mutations (5 papers), Acute Lymphoblastic Leukemia research (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). The work is most often cited by research in Genetics (926 citations), Pathology and Forensic Medicine (1.3k citations), Neurology (725 citations), Oncology (662 citations) and Hematology (120 citations). Samar Issa has collaborated with scholars based in New Zealand, Australia and United States. Frequent co-authors include David Simpson, Peter Wood, Kathryn S. Kolibaba, Ian W. Flinn, David MacDonald, John M. Burke, Tim E. Hawkins, Brad S. Kahl, Doreen M. Hallman and Richard van der Jagt. Their work appears in journals such as Blood, Journal of Clinical Oncology, Neuro-Oncology, Hematological Oncology and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact